Centralized Filings To Increase Under European Pharmaceutical Legislation
This article was originally published in The Pink Sheet Daily
Executive Summary
Legislation mandates that AIDS, cancer, diabetes and neurodegenerative products be centrally filed through EMEA. Roughly 100% of applications filed in Europe are expected to go through the centralized process when the legislation goes into effect in November, according to EMEA Executive Director Thomas Löngrenn.